A Phase II, Single-Arm, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Idasanutlin Monotherapy In Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Study of Experimental Drug Therapy in Patients with Polycythemia Vera (PV)
Sponsor: F. Hoffmann- La Roche Ltd.
Enrolling: Male and Female Patients
Study Length: 2 Years
IRB Number: AAAR4907
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to collect information on whether idasanutlin is effective in treating polycythemia vera (a slow-growing blood cancer in which your bone marrow makes too many red blood cells) and what effects, good or bad, idasanutlin has on you. Idasanutlin is an experimental drug, which means Health Authorities (such as the US FDA) have not approved it for the treatment of PV or any other form of cancer. If you are eligible, you may participate in this study for approximately 2 years.
This study is closed
Mark Heaney, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with polycythemia vera? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator